Azenta Q1 revenue $149M flat; GAAP EPS -$0.11; non-GAAP EPS $0.09; reaffirms FY2026 guidance

Azenta, Inc.

2026-Q1 EPS reported -$0.34 revenue$148,642,000

Revenue $149M (+1% YoY); organic revenue -1%. Sample Mgmt $81M flat; Multiomics $67M (+1%).
GAAP diluted EPS from continuing ops -$0.11 (vs -$0.16); total diluted EPS -$0.34. Non-GAAP EPS $0.09 (vs $0.12).
Gross margin 42.9% (down 380bps) on lost leverage & rework costs; operating margin -4.9%.
Adjusted EBITDA $13M, margin 8.5% (down 230bps). Board authorized $250M share repurchase program through Dec 2028.
Definitive agreement to sell B Medical Systems for $63M; close expected by March 31, 2026. FY2026 guidance reaffirmed: organic rev growth 3-5%, ~300bps adj EBITDA margin expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.